Corrigendum: Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation [Rheumatology, 55, (2016), (2220-2229)] doi:10.1093/rheumatology/kew325;Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation

Rheumatology (United Kingdom)

Volumn 55, Issue 2, 2016, Pages 2220-2229

  Cavalli, Giulio ^a,b,c   Koenders, Marije ^c   Kalabokis, Vassili ^d   Kim, Jihye ^e   Tan, Aik Choon ^e   Garlanda, Cecilia ^f   Mantovani, Alberto ^f   Dagna, Lorenzo ^b   Joosten, Leo A B ^c   Dinarello, Charles A ^a,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d R and D Systems Inc   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f Research Institute Humanitas   (Italy)

Author keywords

Chemokines; Cytokine; IL 1b; Immunotherapy; Neutrophils; Rheumatoid arthritis; TNF a

Indexed keywords

CXCL3 CHEMOKINE; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 37; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; IL18R1 PROTEIN, MOUSE; IL37 PROTEIN, HUMAN; INTERLEUKIN 1; INTERLEUKIN 18 RECEPTOR ALPHA; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL ARTHRITIS; GENE EXPRESSION; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA ISOLATION; SYNOVIUM; ANIMAL; ARTHRITIS, EXPERIMENTAL; C57BL MOUSE; CELL WALL; CHEMISTRY; HUMAN; METABOLISM; PERITONITIS; STREPTOCOCCUS; SYNOVITIS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; CELL WALL; CYTOKINES; HUMANS; INTERLEUKIN-1; INTERLEUKIN-18 RECEPTOR ALPHA SUBUNIT; MALE; MICE, INBRED C57BL; PERITONITIS; RECOMBINANT PROTEINS; STREPTOCOCCUS; SYNOVIAL MEMBRANE; SYNOVITIS;

EID: 85017400198     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex348     Document Type: Erratum

References (38)

1. Banchereau J, Pascual V, O'Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol 2012;13:925-31.
2. Nold MF, Nold-Petry CA, Zepp JA et al. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010;11:1014-22.
3. Dinarello CA, Bufler P. Interleukin-37. Semin Immunol 2013;25:466-8.
4. Bulau AM, Nold MF, Li S et al. Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses. Proc Natl Acad Sci USA 2014;111:2650-5.
5. Kumar S, Hanning CR, Brigham-Burke MR et al. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase- 1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine 2002;18:61-71.
6. McNamee EN, Masterson JC, Jedlicka P et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci USA 2011;108:16711-6.
7. Cai X, Luo Y, Nold-Petry C et al. IL-37 suppresses contact hypersensitivity by inhibiting maturation of dendritic cells. J Invest Dermatol 2011;131:S102.
8. Luo Y, Cai X, Liu S et al. Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci USA 2014;111:15178-83.
9. Bulau AM, Fink M, Maucksch C et al. In vivo expression of interleukin-37 reduces local and systemic inflammation in concanavalin A-induced hepatitis. ScientificWorldJournal 2011;11:2480-90.
10. Ballak DB, van Diepen JA, Moschen AR et al. IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun 2014;5:4711.
11. Garlanda C, Riva F, Polentarutti N et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci USA 2004;101:3522-6.
12. Pan G, Risser P, Mao W et al. IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine 2001;13:7.
13. CromartieWJ, Craddock JG, Schwab JH, Anderle SK, Yang CH. Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med 1977;146:1585-602.
14. Heinhuis B, Koenders MI, van de Loo FA et al. IL-32g and Streptococcus pyogenes cell wall fragments synergise for IL-1-dependent destructive arthritis via upregulation of TLR-2 and NOD2. Ann Rheum Dis 2010;69:1866-72.
15. van den Broek MF, van den Berg WB, van de Putte LB, Severijnen AJ. Streptococcal cell wall-induced arthritis and flare-up reaction in mice induced by homologous or heterologous cell walls. Am J Pathol 1988;133:139-49.
16. Joosten LA, Koenders MI, Smeets RL et al. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J Immunol 2003;171:6145-53.
17. Kuiper S, Joosten LAB, Bendele AM et al. Different roles of tumour necrosis factor a and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine 1998;10:690-702.
18. Joosten LA, Helsen MM, van Den Berg WB. Blockade of endogenous interleukin 12 results in suppression of murine streptococcal cell wall arthritis by enhancement of interleukin 10 and interleukin 1Ra. Ann Rheum Dis 2000;59:196-205.
19. Lubberts E, Joosten LA, Helsen MM, van den Berg WB. Regulatory role of interleukin 10 in joint inflammation and cartilage destruction in murine streptococcal cell wall (SCW) arthritis. More therapeutic benefit with IL-4/IL-10 combination therapy than with IL-10 treatment alone. Cytokine 1998;10:361-9.
20. Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IP. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009;5:554-9.
21. Garlanda C, Di Liberto D, Vecchi A et al. Damping excessive inflammation and tissue damage in Mycobacterium tuberculosis infection by Toll IL-1 receptor 8/single Ig IL-1-related receptor, a negative regulator of IL-1/TLR signaling. J Immunol 2007;179:3119-25.
22. Moretti S, Bozza S, Oikonomou V et al. IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis. PLoS Path 2014;10:e1004462.
23. Wald D, Qin J, Zhao Z et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2003;4:920-7.
24. Nold-Petry CA, Lo CY, RudloffI et al. IL-37 requires the receptors IL-18Ra and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol 2015;16:354-65.
25. Li S, NeffCP, Barber K et al. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proc Natl Acad Sci USA 2015;112:2497-502.
26. Garlanda C, Riva F, Bonavita E, Gentile S, Mantovani A. Decoys and regulatory ''receptors'' of the IL-1/Toll-like receptor superfamily. Front Immunol 2013;4:180.
27. Ye L, Jiang B, Deng J et al. IL-37 alleviates rheumatoid arthritis by suppressing IL-17 and IL-17-triggering cytokine production and limiting Th17 cell proliferation. J Immunol 2015;194:5110-9.
28. Plater-Zyberk C, Joosten LA, Helsen MM et al. GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice. Ann Rheum Dis 2007;66:452-7.
29. Cascão R, Rosário HS, Souto-Carneiro MM, Fonseca JE. Neutrophils in rheumatoid arthritis: more than simple final effectors. Autoimmun Rev 2010;9:531-5.
30. Scapini P, Carletto A, Nardelli B et al. Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. Blood 2005;105:830-7.
31. Auer J, Bläss M, Schulze-Koops H et al. Expression and regulation of CCL18 in synovial fluid neutrophils of patients with rheumatoid arthritis. Arthritis Res Ther 2007;9:R94.
32. Assi LK, Wong SH, Ludwig A et al. Tumor necrosis factor a activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis Rheum 2007;56:1776-86.
33. Vossenaar ER, Nijenhuis S, Helsen MM et al. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum 2003;48:2489-500.
34. Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology 2015;54:2134-44.
35. Vermeij EA, Broeren MG, Bennink MB et al. Diseaseregulated local IL-10 gene therapy diminishes synovitis and cartilage proteoglycan depletion in experimental arthritis. Ann Rheum Dis 2015;74:2084-91.
36. van Roon J, Wijngaarden S, Lafeber FP et al. Interleukin 10 treatment of patients with rheumatoid arthritis enhances Fc gamma receptor expression on monocytes and responsiveness to immune complex stimulation. J Rheumatol 2003;30:648-51.
37. Schwager K, Kaspar M, Bootz F et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinicalstage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 2009;11:R142.
38. Saadoun D, Rosenzwajg M, Joly F et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. New Engl J Med 2011;365:2067-77.